[April 10, 2014] |
|
T2 Biosystems Presents New Data at the Thrombosis and Hemostasis Summit of North America Demonstrating Ability of T2MR Platform Technology to Measure Platelet Activity and Additional Hemostasis Parameters
LEXINGTON, Mass. --(Business Wire)--
T2 Biosystems, a company developing direct detection products designed
to enable superior diagnostics, today announced the presentation of data
highlighting the role of its T2MR platform technology in measuring
platelet function, an important parameter in assessing hemostasis and
thrombosis. The company will also present data on the use of T2MR to
deliver multiplex hemostasis results that include clotting time and
fibrinogen generated by the company's investigational T2Stat instrument
and T2HemoStat panel, which run on the T2MR platform. The T2Stat
instrument and T2HemoStat panel are currently under development for the
potential identification and management of patients suspected of
bleeding disorders, such as the acute coagulopathy of trauma. The data
will be presented at the Thrombosis and Hemostasis Summit of North
America (THSNA), being held in Chicago, IL April 10-12, 2014.
The research being presented at THSNA builds on previous studies related
to T2MR with an expanded data set that shows significant correlation of
platelet activity measurement with light transmission aggregometry
(LTA), the current clinical standard for platelet function testing. This
correlation was achieved on a T2Stat instrument using a small volume (36
µl) of whole blood with no need for sample preparation, whereas
performing the LTA assay required highly trained laboratory
professionals, up to 25 mL of blood, and significant sample manipulation
and hands-on time. The T2HemoStat assay, using T2MR technology, provided
a result in approximately 20 minutes compared to a minimum of 1.5 hours
to more than a day for LTA.
"The ability to rapidly identify bleeding disorders and monitor
hemostasis in trauma ptients could provide clinicians with critical
information to save lives and improve the quality and costs of patient
care," said Mitchell Cohen, MD, Director of Trauma Research at San
Francisco General Hospital. "The challenge with existing approaches to
monitoring these patients is that multiple test results from several
different instruments are required, many of which are time-consuming,
complex and usually restricted to specialized laboratories. This process
often takes too long, leading to delays in treatment that can impact the
health of the patient. This data provides evidence of excellent
correlation of T2MR with the lengthy and complex gold standard of LTA
and further supports the potential of this technology to address the
limitations of the current standard of care."
Each year in the United States, more than three million patients present
with trauma and signs of impaired hemostasis (the process that causes
bleeding to stop). These patients require rapid and frequent assessments
to guide clinical decisions regarding the appropriate blood products,
therapies and surgical interventions needed to balance their fluctuating
hemostasis state. The investigational T2HemoStat panel is designed to
characterize multiple critical hematologic factors, including platelet
function, coagulation and fibrinolysis, using very small samples of
whole blood on a single T2Stat instrument within 20 minutes, allowing
for more informed treatment decisions in high-intensity trauma settings.
"T2 Biosystems is committed to demonstrating the potential value of our
T2MR technology platform through the development of diagnostic tests
that may impact clinical decision-making to improve the health of the
patient and reduce the costs of healthcare," said John McDonough,
President and Chief Executive Officer of T2 Biosystems. "The data
presented at THSNA provides further evidence of the potential for T2MR
technology to make hemostasis testing accessible to healthcare
professionals in a variety of care settings, and to provide clinically
valuable, rapid and reliable insights into platelet function and other
hemostasis measurements."
About T2 Biosystems
T2 Biosystems is developing clinical diagnostics powered by T2MR, a
significant advance in detection technology that is designed to deliver
superior sensitivity quickly to guide more effective clinical
decision-making. T2 Bio is developing a pipeline of molecular
diagnostics and hemostasis products focused on conditions where rapid
and accurate results may have a significant impact on patients' lives
and healthcare costs. The Company's lead products under development, the
T2Candida and T2Bacteria panels, are designed to identify
life-threatening pathogens associated with sepsis directly from whole
blood in a matter of hours, compared to the two to five days required
with blood culture.
T2Candida is for investigational use only. The performance
characteristics of this product have not been established.
T2HemoStat, T2Stat, and T2Bacteria are for Research Use Only. They are
not intended for use in diagnostic procedures.
T2 Biosystems®, T2MR®, T2Candida® are registered trademarks of T2
Biosystems, Inc.
T2HemoStat™, T2Stat™, and T2Bacteria™ are trademarks of T2
Biosystems, Inc.
[ Back To TMCnet.com's Homepage ]
|